Secondary prevention of alcohol problems in health care has been proved efficacious in many studies, yet its implementation remains scarce, and its effectiveness in regular health care remains unknown. This article reports results from a feasibility study of dissemination of alcohol prevention methods in primary health care in Stockholm. Initial interviews with general practitioners (GPs) and district health nurses indicated that few raised the issue of alcohol with patients, made notes about alcohol in patient charts or found working with alcohol issues rewarding. The impact of a training session, where a project nurse visited all willing GPs and nurses, was limited. Although the uptake of the prevention package was high, follow-up at 3 months indicated that little use was made of the materials. Specifically, screening rates were low. In the future, secondary prevention of alcohol problems will require better adaptation to the realities of primary care.

The aim of this study was to assess baseline levels and changes in plasma fatty acid profiles in children and adolescents with ADHD, in a placebo-controlled study with Omega 3/6 supplementation, and to compare with treatment response. Seventy-five children and adolescents aged 8-18 years with DSM-IV ADHD were randomized to 3 months of Omega 3/6 (Equazen eye q) or placebo, followed by 3 months of open phase Omega 3/6 for all. n-3, n-6, n-6/n-3 ratio, EPA and DHA in plasma were measured at baseline, 3 and 6 months. Subjects with more than 25 % reduction in ADHD symptoms were classified as responders. At baseline, no significant differences in mean fatty acid levels were seen across active/placebo groups or responder/non-responder groups. The 0-3 month changes in all parameters were significantly greater in the active group (p < 0.01). Compared to non-responders, the 6-month responders had significantly greater n-3 increase at 3 months and decrease in n-6/n-3 ratio at 3 and 6 months (p < 0.05). Omega 3/6 supplementation had a clear impact on fatty acid composition of plasma phosphatidyl choline in active versus placebo group, and the fatty acid changes appear to be associated with treatment response. The most pronounced and long-lasting changes for treatment responders compared to non-responders were in the n-6/n-3 ratio.

The distribution of phenotypes of alpha-1-antitrypsin (Pi) in 1,062 unrelated Swedes was determined by isoelectric focusing with carrier ampholytes. The frequencies calculated were: Pi^M1 = 0.6940, Pi^M2 = 0.1384, Pi^M3 = 0.1139, P^iz= 0.0231, P^is = 0.0245, P^iF = 0.0038, Pi^var = 0.0024. A mother-child material consisting of 194 pairs is also presented.

No abstract

Five new genetically determined Gc variants were observed by isoelectric focusing. Seven rare variants 1A4, 1Cl, 1C3, 1C9, 1C11, 2A2, and 2A5 were also found in the material comprising Danish and Swedish paternity cases. All the variants were further analysed by electrophoresis in agarose gel. Two of the new variants had double bands of which the anodal one was susceptible to neuraminidase treatment (Gc 1C13 and 1C14). The three other new variants appeared as a single band, which was unaffected by neuraminidase treatment (Gc 2A9, 2C5, and 2C6). The Gc Ar variant originally detected by electrophoresis was reexamined by isoelectric focusing and named 2C4.